Two Lymphoma Foundations Merge to Form the Lymphoma Research Foundation

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 4
Volume 11
Issue 4

LOS ANGELES-The Lymphoma Research Foundation of America (LRFA) and the New York-based Cure For Lymphoma Foundation (CFL) have merged to become the Lymphoma Research Foundation (LRF), the nation’s only organization dedicated solely to funding lymphoma research and providing information, education, and support to all those touched by the disease.

LOS ANGELES—The Lymphoma Research Foundation of America (LRFA) and the New York-based Cure For Lymphoma Foundation (CFL) have merged to become the Lymphoma Research Foundation (LRF), the nation’s only organization dedicated solely to funding lymphoma research and providing information, education, and support to all those touched by the disease.

By reducing duplicative administrative and program costs, the new foundation expects to be able to enhance its services to patients, caregivers, and health care professionals.

LRFA and CFL have a collective 17 years of experience and have funded more than $7 million in lymphoma research. The new LRF will continue to fund basic, translational, and clinical research projects at the fellow and junior faculty levels.

The new foundation has offices in Los Angeles, focusing on patient services and educational and support programs, and New York, focusing on research grants, public policy and advocacy, finance and development, and professional education. More information is available online at www.lymphoma.org.

Recent Videos
Genetic consultation and next-generation sequencing can also complement treatment strategies for patients with pancreatic cancer.
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
Related Content